Sign In
Section Navigation
Common TitleAI438-006
Official Title Randomized, Open Label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Fostemsavir (BMS-663068) in HIV-1 Infected Subjects
Phase Phase IIA
ClinicalTrials.gov NCT01009814
Treatments
Fostemsavir
Fostemsavir Rukobia

Fostemsavir

Tradename:RukobiaOther Names:FTRClass:Entry Inhibitors
Categories PharmacologyTreatment-NaiveTreatment-ExperiencedGeneral PharmacologyResistance/Virological Failure
Funding
IndustryBristol-Myers Squibb
References
  • Nettles RE, Schürmann D, Zhu L, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012;206:1002-11.
    [PubMed Abstract]
  • Ray N, Hwang C, Healy MD, et al. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 2013;64:7-15.
    [PubMed Abstract]
  • Zhou N, Nowicka-Sans B, McAuliffe B, et al. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J Antimicrob Chemother. 2014;69:573-81.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.